Commodore Capital LP Trims Holdings in Mind Medicine (MindMed) Inc. $MNMD

Commodore Capital LP trimmed its stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) by 38.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 2,000,000 shares of the company’s stock after selling 1,225,000 shares during the period. Mind Medicine (MindMed) accounts for about 1.8% of Commodore Capital LP’s investment portfolio, making the stock its 23rd biggest position. Commodore Capital LP’s holdings in Mind Medicine (MindMed) were worth $26,780,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in MNMD. Concurrent Investment Advisors LLC purchased a new stake in shares of Mind Medicine (MindMed) in the 4th quarter valued at approximately $273,000. UBS Group AG increased its stake in Mind Medicine (MindMed) by 23.9% during the 4th quarter. UBS Group AG now owns 683,802 shares of the company’s stock worth $9,156,000 after buying an additional 131,993 shares during the period. Jennison Associates LLC purchased a new stake in Mind Medicine (MindMed) during the 4th quarter worth approximately $720,000. PSP Research LLC purchased a new stake in Mind Medicine (MindMed) during the 4th quarter worth approximately $467,000. Finally, Royce & Associates LP increased its stake in Mind Medicine (MindMed) by 102.5% during the 4th quarter. Royce & Associates LP now owns 164,041 shares of the company’s stock worth $2,197,000 after buying an additional 83,017 shares during the period.

Mind Medicine (MindMed) Stock Performance

Shares of MNMD opened at $0.69 on Thursday. The firm’s fifty day moving average is $0.69.

Mind Medicine (MindMed) (NASDAQ: MNMD) is a clinical-stage biotechnology company focused on developing psychedelic-inspired medicines and accompanying therapeutic protocols to treat mental health disorders and substance use disorders. The company’s research emphasizes both novel small molecules and established psychedelic compounds used in controlled, clinically supervised settings, with the goal of creating safe, scalable treatments that combine pharmacology with psychotherapy.

MindMed’s activities include preclinical research, clinical trials, and the development of treatment delivery models and protocols that integrate drug administration with therapeutic support.